Rein Therapeutics, Inc. (RNTX): Operating Income
-$50.63M
Year ended 2025-12-31
-$49.46M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$50.63M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$65.11M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$16.28M | n/m | 2025-04-07, From 2023-01-01 |
| 2022-12-31 | -$27.65M | n/m | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | -$26.61M | n/m | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | -$20.50M | n/m | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | -$29.96M | n/m | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | -$31.90M | n/m | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | -$23.01M | n/m | 2019-03-29, From 2017-01-01 |
| 2016-12-31 | -$18.17M | n/m | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | -$12.89M | n/a | 2018-04-02, From 2015-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | -$50.63M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.39M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.21M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
Compare RNTX, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗